Optical Coherence Tomography Assessment of Intimal Tissue and Malapposition

NCT ID: NCT01137019

Last Updated: 2014-08-05

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-10-31
• Study Completion Date: 2014-12-31

Brief Summary

The purpose of this study is to use a high-resolution intracoronary imaging modality, called optical coherence tomography (OCT) to examine two different types of coronary artery stents used to treat patients with coronary artery disease.

Detailed Description

The development of coronary stents has significantly improved the safety and efficacy of percutaneous coronary intervention (PCI) compared to balloon angioplasty alone. Nevertheless, restenosis is still encountered in 20 to 40% of coronary lesions after implantation of bare metal stents, inferring frequent repeat revascularization procedures with a negative impact on quality of life and health care expenditures. Drug-eluting stents (DES), with their controlled release of therapeutic agents, have significantly reduced the rate of major adverse cardiac events (MACE) following coronary stent implantation, primarily by a reduction in restenosis and target lesion revascularization.

Optical coherence tomography (OCT) is an optical analogue of intravascular ultrasound (IVUS): it uses an infrared light source (wavelength 1310nm) and measures the backscatter of light in a technique similar to conventional ultrasound. With this technique a resolution up to 10μm in-vivo has been reported, a far better level of resolution compared with IVUS. Optical coherence tomography has been used in vivo and has detected early atherosclerotic plaques previously not visualised by IVUS. Segments with strut malapposition and the presence or thickness of neointimal hyperplasia can also be more accurately assessed with OCT compared with IVUS.

The present study will utilize the imaging capabilities of OCT to assess stent strut malapposition and tissue coverage in two different types of DES. The biolimus-eluting stent eludes biolimus from a biodegradable polylactic acid polymer on the abluminal surface of a stainless steel stent. This stent will be compared in a randomized fashion to the permanent polymer based everolimus-eluting coronary stent made of cobalt chromium alloy.

Conditions

Coronary Heart Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Biolimus-eluting stent

Group Type: ACTIVE_COMPARATOR

Biolimus-eluting stent

Intervention Type: DEVICE

The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9.

Everolimus-eluting stent

Group Type: ACTIVE_COMPARATOR

Everolimus-eluting coronary stent

Intervention Type: DEVICE

The everolimus-eluting coronary stent is a cobalt chromium platform stent with a permanent fluorinated copolymer matrix that eludes everolimus

Interventions

Biolimus-eluting stent

The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9.

Intervention Type: DEVICE

Everolimus-eluting coronary stent

The everolimus-eluting coronary stent is a cobalt chromium platform stent with a permanent fluorinated copolymer matrix that eludes everolimus

Intervention Type: DEVICE

Other Intervention Names

Biomatrix Flex (Biosensors International); Promus (BSC)

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years
• Symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes including non-ST elevation myocardial infarction
• Presence of one or more coronary artery stenosis > 50% in a native coronary artery with a reference diameter ranging from 2.25 to 4.0 mm which can be covered with one or multiple stents
• No limitation to the number of treated lesions, number of vessels or lesion length according to the randomization group

Exclusion Criteria

• Known intolerance to aspirin, clopidogrel, heparin, stainless steel, cobalt chromium, Biolimus, everolimus, contrast material
• Acute ST-segment elevation myocardial infarction
• Bypass graft
• Inability to provide informed consent
• Pregnancy
• Planned surgery within 12 months of PCI unless dual antiplatelet therapy is maintained throughout the peri-surgical period
• Left ventricular ejection fraction < 25%
• Serum creatinine > 180mmol/L

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Biosensors International

OTHER

Sponsor Role: collaborator

Dr Peter Barlis

OTHER

Sponsor Role: lead

Responsible Party

Dr Peter Barlis

Associate Professor of Medicine, Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Peter Barlis, MBBS PhD FRACP

Role: PRINCIPAL_INVESTIGATOR

Northern Hospital, Department of Cardiology, Victoria, Australia

Locations

The Northern Hospital

Epping, Victoria, Australia

Countries

Australia

References

Barlis P, Regar E, Serruys PW, Dimopoulos K, van der Giessen WJ, van Geuns RJ, Ferrante G, Wandel S, Windecker S, van Es GA, Eerdmans P, Juni P, di Mario C. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J. 2010 Jan;31(2):165-76. doi: 10.1093/eurheartj/ehp480. Epub 2009 Nov 4.

Reference Type: BACKGROUND

PMID: 19889649 (View on PubMed)

Barlis P, van Soest G, Serruys PW, Regar E. Intracoronary optical coherence tomography and the evaluation of stents. Expert Rev Med Devices. 2009 Mar;6(2):157-67. doi: 10.1586/17434440.6.2.157.

Reference Type: BACKGROUND

PMID: 19298163 (View on PubMed)

Barlis P, Dimopoulos K, Tanigawa J, Dzielicka E, Ferrante G, Del Furia F, Di Mario C. Quantitative analysis of intracoronary optical coherence tomography measurements of stent strut apposition and tissue coverage. Int J Cardiol. 2010 May 28;141(2):151-6. doi: 10.1016/j.ijcard.2008.11.204. Epub 2009 Jan 19.

Reference Type: BACKGROUND

PMID: 19155076 (View on PubMed)

Tanigawa J, Barlis P, Dimopoulos K, Dalby M, Moore P, Di Mario C. The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography. Int J Cardiol. 2009 May 15;134(2):180-8. doi: 10.1016/j.ijcard.2008.05.069. Epub 2008 Sep 4.

Reference Type: BACKGROUND

PMID: 18775576 (View on PubMed)

Other Identifiers

OPTIMA A19/10

Identifier Type: -

Identifier Source: org_study_id